Chicago's Seurat Therapeutics raised $750K to treat migraines with a nasal spray

Seurat Therapeutics, a Chicago biotech startup that’s developing a nasal spray to treat and prevent migraines, has raised its first round of funding that will allow the company to begin testing their product in human clinical trials.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.